<DOC>
	<DOCNO>NCT01723839</DOCNO>
	<brief_summary>In previously-untreated subject CLL , fludarabine rituximab without cyclophosphamide ( FR FCR ) produce complete response ( CR ) 40-80 % . The major complication FCR grade 3/4 neutropenia reduce use low dose fludarabine cyclophosphamide ( FCR-Lite ) The objective study evaluate minimal residual disease ( MRD ) complete response rate ( use 2008 IWCLL guideline ) 4 cycle FCR-Lite plus lenalidomide subject previously untreated CLL . Lenalidomide active frontline treatment CLL well patient refractory disease . MRD demonstrate sensitive surrogate marker progression-free survival . If patient MRD negative complete responder ( CR ) stop 4 cycle FCR-Lite follow lenalidomide consolidation/maintenance arm study . If MRD positive CR partial response ( PR ) continue 2 additional cycle FCR-Lite plus lenalidomide follow lenalidomide consolidation/maintenance . They re-tested MRD 6th cycle FCR-Lite 6 12 month lenalidomide monotherapy If response ( NR ) progressive disease ( PD ) follow 4 cycle FCR-Lite plus lenalidomide remove study .</brief_summary>
	<brief_title>Phase II Protocol CLL With Fludarabine Cyclophosphamide With Rituximab ( FCR ) Plus Lenalidomide</brief_title>
	<detailed_description>STUDY OBJECTIVES : Primary : The primary objective evaluate complete response rate follow 4 cycle FCR-Lite plus lenalidomide previously untreated patient CLL . Secondary : The first secondary objective evaluate toxicity patient previously untreated CLL treat FCR-Lite plus lenalidomide , follow lenalidomide . The second evaluate overall response rate overall survival patient previously untreated CLL treat FCR-Lite plus lenalidomide follow lenalidomide . The third determine whether add lenalidomide consolidation/maintenance therapy eliminate bone marrow minimal residual disease CR patient whether patient PR 6 cycle FCR-Lite plus lenalidomide respond 12 month lenalidomide . The final secondary objective determine whether expression ZAP-70 , CD38 , chromosomes correlate response rate , duration response , survival previously untreated patient CLL . STUDY DESIGN : 2-stage phase 2 study-design . 19 subject treat stage-1 FCR-Lite plus 5mg lenalidomide increase 10mg 15mg subsequent cycle depend toxicity . If least 5 CRs study accrue additional 35 subject ( see statistical section ) . A secondary objective study determine MRD positive patient become MRD negative lenalidomide consolidation/maintenance whether PR patient convert CRs Lenalidomide begin 2 month last dose FCR-Lite subject CR . It may begin soon 1 month FCR-Lite plus lenalidomide subject PR . Lenalidomide give 28 cycle increase dose 5 mg/d 10 mg/d cycle 2 15mg cycle 3-6 well- tolerate ( grade-3 -4 toxicity ) . Patients creatinine clearance ≥30ml/min &lt; 60ml/min start 2.5mg daily increase 5 10mg subsequent cycle . Reduction prior dose allow grade-3/-4 toxicity . MRD study flow cytometry bone marrow peripheral blood sample follow 4 6 cycle FCR-Lite 6 12 month lenalidomide CR patient .</detailed_description>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must diagnosis CLL ( define NCI Criteria : Patients must peripheral blood absolute lymphocyte count &gt; 5,000/mm3 obtain within 2 week prior start study . The lymphocytosis must consist small , mature lymphocyte , ≤55 % ( great 55 % ) prolymphocytes . Patients must phenotypically characterize CLL define : 1 . The predominant population cell share Bcell antigens CD5 absence panTcell marker ( CD3 , CD2 , etc . ) ; 2 . Surface immunoglobulin ( slg ) CD20 lowcell surface density expression . 3 . If surface immunoglobulin demonstrate , leukemic cell restrict expression either kappa lambda . Splenomegaly , hepatomegaly lymphadenopathy require diagnosis CLL Patients must require chemotherapy Patients must receive prior treatment cytotoxic , immunotherapy investigational therapy . Patients must history corticosteroid treatment CLL , Autoimmune thrombocytopenia , autoimmune hemolytic anemia . Calculated creatinine clearance ≥30ml/min CockcroftGault formula Bilirubin must ≤1.5mg/dl , unless secondary tumor , obtain within 2 week prior registration Platelets ≥75x109/L , unless due CLL involvement bone marrow Neutrophils ≥1.5x109/L , unless due CLL involvement bone marrow AST ALT &lt; 2x upper limit normal , unless relate CLL Age ≥18 year ECOG performance status 02 Females childbearing potential ( FCBP ) must negative serum urine pregnancy test Men must agree use latex condom sexual contact FCBP even successful vasectomy Able take aspirin ( 81mg 325mg ) daily prophylactic anticoagulation Subject must provide write informed consent All study participant must register mandatory RevAssist® program , willing able comply requirement RevAssist® Patients autoimmune hemolytic anemia autoimmune thrombocytopenia eligible No prior immunotherapy , investigational cytotoxic chemotherapy Patients history steroid treatment CLL/SLL autoimmune hemolytic anemia , autoimmune thrombocytopenia eligible Patients active infection require oral intravenous ( IV ) antibiotic resolution infection completion therapeutic antibiotic Women childbearing potential sexually active male refuse use accept effective method contraception woman breastfeed Patients second malignancy basal cell carcinoma squamous cell carcinoma skin situ carcinoma cervix eligible unless tumor treat curative intent least two year previously History know HIV History presence CNS disease Evidence laboratory TLS CairoBishop definition Tumor Lysis Syndrome History corticosteroid treatment CLL , Autoimmune thrombocytopenia , autoimmune hemolytic anemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>CLL</keyword>
	<keyword>FCR</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Cyclophosphamide</keyword>
</DOC>